Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma. Li L, Zhang Y, Zhou Y, Hu H, et al. Hepatology 2022 May 21. doi: 10.1002/hep.32584.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li L, Zhang Y, Zhou Y, Hu H, et al. Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma. Hepatology 2022 May 21. doi: 10.1002/hep.32584.
PMID: 35596926